References
- Marlen J, Mulliken J. Current management of hemangiomas and vascular malformations. Clin Plast Surg. 2005;32:99–116.
- Drolet B, Esterly N, Frieden I. Hemangiomas in children. N Engl J Med. 1999;341:173–81.
- Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358:2649–51.
- Léauté-Labrèze C. [Propranolol in infantile hemangiomas]. Arch Pediatr. 2015;22:452–55.
- Rössler J, Haubold M, Gilsbach R, et al. β1-Adrenoceptor mRNA level reveals distinctions between infantile hemangioma and vascular malformations. Pediatr Res. 2013;73:409–13.
- Stiles J, Amaya C, Pham R, et al. Propranolol treatment of infantile hemangioma endothelial cells: a molecular analysis. Exp Ther Med. 2012;4:594–604.
- Lee D, Boscolo E, Durham JT, et al. Propranolol targets the contractility of infantile haemangioma-derived pericytes. Br J Dermatol. 2014;171:1129–37.
- Ji Y, Chen S, Li K, et al. The role of β-adrenergic receptor signaling in the proliferation of hemangioma-derived endothelial cells. Cell Div. 2013;8:1.
- Blanke K, Dähnert I, Salameh A. Role of connexins in infantile hemangiomas. Front Pharmacol. 2013;4:41.
- Zhang L, Mai HM, Zheng J, et al. Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell. Int J Clin Exp Pathol. 2014;7:48–55.
- Wong A, Hardy KL, Kitajewski AM, et al. Propranolol accelerates adipogenesis in hemangioma stem cells and causes apoptosis of hemangioma endothelial cells. Plast Reconstr Surg. 2012;130:1012–21.
- Zegbi-Trueba MS, Abarzúa-Araya A, Silva-Valenzuela S, et al. Oral propranolol for treating infantile hemangiomas: a case series of 57 patients. Actas Dermosifiliogr. 2012;03:708–17.
- El Ezzi O, Hohlfeld J, de Buys Roessingh A. Propranolol in infantile haemangioma: simplifying pretreatment monitoring. Swiss Med Wkly. 2014;144:w13943.
- Ma X, Zhao T, Xiao Y, et al. Preliminary experience on treatment of infantile hemangioma with low-dose propranolol in China. Eur J Pediatr. 2013;172:653–59.
- Xiao Q, Li Q, Zhang B, et al. Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence. Pediatr Surg Int. 2013;29:575–81.
- Shupp CJ, Kleber JB, Günther P, et al. Propranolol therapy in 55 infants with infantile hemangioma: dosage, duration, adverse effects and outcome. Pediatr Dermatol. 2011;28:640–44.
- Chu DH, Castelo-Soccio L, Wan J, et al. Retrospective analysis of beta-blocker instituted for treatment of hemangiomas (RABBIT study). Clin Pediatr (Phila). 2014;53:1084–90.
- Filippi L, Cavallaro G, Fiorini P, et al. Propranolol concentrations after oral administration in term and preterm infants. J Matern Fetal Neonatal Med. 2013;26:833–40.
- National high blood pressure education program working group on high blood pressure in children and adolescents. The fourth report on diagnosis, evaluation and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555–76.
- Bernstein D, Evaluation of the cardiovascular system. In Kliegman RM, Stanton BF, St. Geme JW, et al., eds. Nelson Textbook of Pediatrics. Philadelphia: Elsevier Saunders, 2011. p 1532.
- Jacks SK, Kertesz NJ, Witman PM, et al. Experience with Holter monitoring during propranolol therapy for infantile hemangiomas. J Am Acad Dermatol. 2015;73:255–57.
- Song H, Shi H, Zhang X, et al. Safety profile of a divided dose of propranolol for heart rate in children with infantile haemangioma during 16 weeks of treatment. Br J Dermatol. 2015;172:444–49.
- Schneider M, Cremer H, Ruef P. A retrospective analysis of systemic propranolol for the treatment of complicated infantile haemangiomas. Acta Paediatr. 2014;103:977–83.
- Stoschitzky K, Sakotnik A, Lercher P, et al. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol. 1999;55:111–15.
- Lou Y, Peng WJ, Cao Y, et al. The effectiveness of propranolol in treating infantile haemangiomas: a meta-analysis including 35 studies. Br J Clin Pharmacol. 2014; 78:44–57.
- Liu X, Tai M, Qin Z, et al. Clinical analysis for treatment of 1080 cases of infantile hemangiomas with oral propranolol. Zhonghua Yi Xue Za Zhi. 2014;94:1878–81.
- Szychta P, Stewart K, Anderson W. Treatment of infantile hemangiomas with propranolol: clinical guidelines. Plast Reconstr Surg. 2014;133:852–62.
- Andersen IG, Rechnitzer C, Charabi B. Effectiveness of propanolol for treatment of infantile haemangioma. Dan Med J. 2014;61:A4776.
- Tan CE, Itinteang T, Leadbitter P, et al. Low-dose propranolol regimen for infantile haemangioma. J Paediatr Child Health. 2014;51:419–24.
- Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372:735–46.